Sharemaestro Newsreel

Harvard Bioscience Lifts 2026 Revenue Outlook After 11% Q2 Growth

Harvard Bioscience (HBIO) reported an 11% year-over-year revenue increase to $22.7 million in Q2 2026, leading them to raise their full-year 2026 revenue growth guidance to 3-5%. Despite a widened GAAP net loss, adjusted EBITDA saw growth, and the company provided Q3 2026 revenue …

Eye care company Alcon raises profitability outlook, cuts tariff hit estimate

Alcon, a Swiss-American eye care company, raised its 2026 profitability target and its guidance for core diluted earnings per share, leading to a 4% jump in shares. This increase was driven by improved margin performance in its Equipment and Ocular Health divisions and a …

Baxter International Inc. (NYSE:BAX) Given Average Recommendation of "Reduce" by Analysts

Thirteen research firms have given Baxter International Inc. (NYSE:BAX) an average rating of "Reduce," with a collective price target of $22.45, below its current trading price of $27.84. Despite this cautious outlook, Baxter International reported strong quarterly results, exceeding analyst expectations with an adjusted …

Baxter International (NYSE:BAX) Stock Crosses Above 200-Day Moving Average - Here's Why

Baxter International (NYSE:BAX) stock recently crossed above its 200-day moving average, trading at $27.84, significantly higher than its average of $19.93. The company reported strong quarterly earnings, exceeding analyst expectations with an adjusted EPS of $0.56 and revenue of $2.96 billion. Despite positive financial …

Intuitive surgical EVP Gary Loeb sells $151,600 in common stock

Gary Loeb, EVP at Intuitive Surgical Inc., sold 400 shares of common stock totaling $151,600 on August 10, 2026, under a pre-arranged trading plan. Despite the sale, the stock has risen and is considered undervalued by InvestingPro, with the company reporting strong Q2 earnings …

Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today

Dentsply Sirona's (XRAY) stock fell 6.8% after its Q2 2026 earnings report, despite beating profit estimates. The decline was primarily driven by a weak full-year revenue forecast, which came in 1% below analyst consensus, raising concerns about the company's future growth prospects. This negative …

Microbot Medical Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter

Microbot Medical has filed its 10-Q report, indicating significant revenue and customer growth during the second quarter of 2026. This suggests positive financial performance for the company in the recent period.

How Icu Medical Inc. (ICUI) Affects Rotational Strategy Timing

This article analyzes Icu Medical Inc. (ICUI) through AI models, identifying strong sentiment across all horizons and no resistance levels above the current price, suggesting upside potential. It outlines three institutional trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk …

Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Brokerages

Repligen Corporation (NASDAQ:RGEN) has received a "Moderate Buy" consensus rating from eighteen brokerages, with an average 12-month price target of $166.43. The company recently surpassed quarterly earnings and revenue expectations, reporting $0.54 EPS and $204.13 million in revenue, an 11.9% year-over-year increase. Despite a …

Embecta Corp. Notice of August 17, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline

Hagens Berman, a national shareholder rights law firm, is investigating Embecta Corp. (NASDAQ: EMBC) for alleged violations of federal securities laws after a class action lawsuit was filed. The lawsuit claims Embecta misrepresented the stability of its insulin pen needle business, leading to a …

Alcon (SWX:ALC), Why Is Its Latest Update Drawing Attention?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Alcon's latest earnings matter for shareholders Alcon (SWX:ALC) has just reported second quarter 2026 results that combine higher sales with lower profits, giving …

What To Expect From STAAR Surgical’s (STAA) Q2 Earnings

STAAR Surgical (STAA) is set to report its Q2 earnings this Wednesday after market hours. Analysts expect a 104% year-on-year revenue growth, a significant reversal from the previous year's decline. Despite past revenue misses, analysts have reconfirmed their estimates, though STAA's share price has …

Stevanato Group (STVN) Could Be 16% Undervalued Following Earnings And Guidance Update

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. What Stevanato Group's latest earnings and guidance mean for investors Stevanato Group (STVN) has …

Insider Selling: Bausch + Lomb (NYSE:BLCO) Director Sells $100,458.22 in Stock

Bausch + Lomb (NYSE:BLCO) director Andrew Von Eschenbach sold 6,059 shares of the company's stock for approximately $100,458 at an average price of $16.58, reducing his ownership by 8.68%. Following this transaction, his remaining stake is valued at over $1 million. The company's stock …

Bausch & Lomb (NYSE: BLCO) director sells 18,559 shares after board exit

Bausch & Lomb Corp director Andrew C. Von Eschenbach sold a total of 18,559 common shares in two open-market transactions on August 6 and 7, 2026, after resigning from the board on August 5, 2026. The sales occurred at weighted average prices of $16.50 …

EMBC INVESTOR ALERT: Embecta Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) for alleged violations of federal securities laws, following a class action lawsuit claiming Embecta misrepresented the commercial stability of its insulin pen needle business. The lawsuit alleges the company's statements about its "stable" and "resilient" pen …

Solventum Doubles Down on Medtech and Plans to Separate Healthcare Information Systems

Solventum is strategically focusing on the Medtech sector and plans to separate its Healthcare Information Systems (HIS) segment. The company, recently spun out, is undergoing a significant restructuring, including the sale of its purification and filtration business to reduce leverage and improve margins. This …

Ord Minnett Remains a Buy on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)

Ord Minnett has maintained a Buy rating on Resmed Inc CHESS Depositary Interests (RMD) with a price target of A$36.20. This positive outlook is echoed by Morgans, while Citi recently assigned a Hold rating. Resmed reported strong financial results for the quarter ending March …

Bionano Genomics Inc (BNGO) (Q2 2026) Earnings Call Highlights: Record Flow Cell Sales and ...

Bionano Genomics Inc (BNGO) reported Q2 2026 revenue of $8.2 million, a 21% year-over-year increase, exceeding guidance, driven by record flow cell sales. Despite strong demand and increased gross margins, the company faces supply constraints for flow cells and a decline in software revenue. …

Contravisory Investment Management Inc. Makes New $1.11 Million Investment in Align Technology, Inc. $ALGN

Contravisory Investment Management Inc. recently invested $1.11 million in Align Technology (NASDAQ:ALGN) by acquiring 6,557 shares in the second quarter. This move is part of broader institutional interest, with hedge funds collectively owning 88.43% of the company. Align Technology has reported strong financial results, …

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know What Happened? Shares of medical device company ICU Medical (NASDAQ:ICUI) jumped 10.2% in the afternoon session after the company posted strong second-quarter results that surpassed Wall Street expectations and raised its full-year earnings forecast. …

Intuitive Surgical (NASDAQ:ISRG) EVP Gary Loeb Sells 400 Shares of Stock

Intuitive Surgical's EVP Gary Loeb sold 400 shares of the company's stock for $151,600, reducing his holdings by almost 7%. This transaction occurred under a pre-arranged trading plan, and the company recently reported strong quarterly earnings, beating analyst expectations with $2.89 billion in revenue …

ICU Medical (ICUI) Following Raised 2026 Guidance Looks Modestly Undervalued

Bionano outlines $31M-$33M 2026 revenue forecast amid flow cell supply constraints

Earnings Call Insights: Bionano Genomics (BNGO) Q2 2026 MANAGEMENT VIEW * "Bionano had a strong second quarter, and that strength can be directly attributed to increased adoption by our customers," said (Chairman, Interim CEO, Interim President & Interim Principal Financial Officer Albert Luderer), adding …

Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Alcon (ALC) reported $2.78 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 8%. EPS of $0.84 for the same period compares to $0.76 a year ago. The reported revenue represents a surprise of +0.58% over the Zacks Consensus …

Alcon rises ahead of earnings as investors bet on product momentum

Alcon (ALC) stock rose 7.2% ahead of its Q2 2026 earnings release, signaling investor optimism. This surge is attributed to positive sentiment surrounding recent product launches, an improved 2026 core EPS outlook, and an expanding eye-care pipeline. The company previously reported strong Q1 2026 …

Intuitive Surgical (ISRG) Just Beat Earnings. Is the Stock Still Worth Paying a Premium?

Intuitive Surgical (ISRG) beat Q2 2026 earnings and revenue estimates, but its stock dropped due to investor concerns about slowing domestic procedure growth. Despite this, UBS upgraded the stock, citing potential for dramatic acceleration in procedure penetration, strong profitability margins, and robust recurring revenue …

Alcon Inc. (ALC) Stock Rises on Q2 2026 Earnings

Alcon Inc. (ALC) reported solid Q2 2026 revenue of $2.8 billion, up 8.7%, and gross profit of $1.7 billion, up 20.7%. Despite this, operating profit and net income fell to $0, indicating increased operating pressure. Investors reacted positively, with the stock rising 5.94% after …

TELEFLEX INCORPORATED : TRUIST SECURITIES RAISES TARGET PRICE TO $150 FROM $143

Truist Securities has increased its target price for Teleflex Incorporated (TFX.N) to $150 from $143. This update indicates a more positive outlook from the securities firm on the medical technology company's stock. The information was reported by Reuters.

Intuitive Surgical Inc. stock outperforms competitors on strong trading day

Intuitive Surgical Inc. (ISRG) saw its stock rise by 3.85% to $393.38 on a generally down day for the market. This performance outpaced major indices like the S&P 500 and Dow Jones Industrial Average, which experienced slight declines. It marked the second consecutive day …

New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth

Second-quarter 2026 sales of $2.8 billion, up 8%on a reported basis, or up 7% constant currency1 (cc), versus second-quarter 2025 Returned $538 million to shareholders through dividends and share repurchases on a year-to-date basis Updated full-year guidance - raised core operating margin and core …

Earnings Flash (ALC) Alcon Inc. Posts Q2 Adjusted EPS $0.84 per Share, vs. FactSet Est of $0.75

Alcon Inc. (ALC) announced its Q2 adjusted EPS of $0.84 per share, surpassing FactSet's estimate of $0.75. The company's Q2 revenue also exceeded expectations, reporting $2.78 billion against an estimated $2.76 billion. This financial news highlights a strong performance for the global ophthalmic care …

Bionano Genomics, Inc. Q2 2026: Revenue $8.17M, EPS $(0.64) — 10-Q Summary

Bionano Genomics, Inc. reported its Q2 2026 financial results, showing a 21% increase in revenue to $8.17M, up from $6.73M in Q2 2025. Despite this growth, the company recorded a net loss of $7.42M, though the diluted EPS improved significantly from $(1.99) to $(0.64) …

Bionano Reports Second Quarter 2026 Results and Provides a Business Update

Bionano has reported its second-quarter 2026 financial results, which include updates on its operational performance and strategic initiatives. The company also provided a comprehensive business update detailing its progress and future outlook.

Nephros (NEPH) boosts Q2 2026 profit on revenue growth and tariff refund

Nephros Inc. (NEPH) reported significant financial growth in Q2 2026, with net revenue up 36% to $6.0 million and net income rising to $1.2 million, largely driven by programmatic product growth and a $0.6 million IEEPA tariff refund. Despite this positive performance, the company …

AtriCure (ATRC) Lifted Its Guidance, Is The Stock Fully Priced?

AtriCure (ATRC) has seen insider share sales despite reporting 13% Q2 revenue growth, returning to net income, and raising full-year guidance. While one valuation narrative suggests the stock is 11.9% undervalued at $47.00 due to potential market expansion from clinical trials, another analysis using …